A systems mechanism for KRAS mutant allele–specific responses to targeted therapy | Science Signaling
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge | Cell Discovery
Cancers | Free Full-Text | Synthetic Vulnerabilities in the KRAS Pathway
Frontiers | KRAS protein expression becomes progressively restricted during embryogenesis and in adulthood
Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides | PNAS
Cancers | Free Full-Text | KRAS G12C Mutations in NSCLC: From Target to Resistance
Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling | PLOS Computational Biology
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
The KRAS-G12C inhibitor: activity and resistance | Cancer Gene Therapy
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer | Nature Reviews Gastroenterology & Hepatology
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials | European Respiratory Society
An overview of upstream and downstream effectors of KRAS. (Figure... | Download Scientific Diagram
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience | Cancer Genomics & Proteomics
Acquired Resistance to KRASG12C Inhibition in Cancer | NEJM
Figure 1 from Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. | Semantic Scholar
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism: Cell
The current understanding of KRAS protein structure and dynamics | Semantic Scholar
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Immune modulatory effects of oncogenic KRAS in cancer | Nature Communications
KRAS G12V Protein, Human, Recombinant, Biotinylated – Amid Biosciences | Protein Engineering Company
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine | Nature Communications
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - Ye Yuan, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, Wenwei Hu, 2021
